A Phase II, Multi-site, Open-label, Dose-titration Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Lu AG13909 in Adults With Cushing's Disease
Latest Information Update: 31 Dec 2024
At a glance
- Drugs Lu AG13909 (Primary) ; Lu AG13909 (Primary)
- Indications Cushing syndrome
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Lundbeck A/S
- 02 Dec 2024 Planned End Date changed from 15 May 2026 to 15 Dec 2027.
- 02 Dec 2024 Planned primary completion date changed from 7 Feb 2026 to 15 Sep 2026.
- 22 Jul 2024 Status changed from not yet recruiting to recruiting.